Navigation Links
New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD
Date:10/26/2009

SAN DIEGO, Oct. 26 /PRNewswire/ -- New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001). In addition, secondary measures showed that KAPIDEX improved relief of nighttime heartburn and GERD-related sleep disturbances (p<0.001). KAPIDEX was approved in January 2009 for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive GERD, the healing of erosive esophagitis (EE) and the maintenance of healed EE.

This multicenter, randomized, double-blind, placebo-controlled clinical trial evaluated the effect of KAPIDEX on subjects with nighttime heartburn symptoms. The study enrolled 305 subjects (ages 18 to 66) with non-erosive symptomatic GERD, who reported having moderate-to-severe nighttime heartburn and GERD-related sleep disturbances on at least three of seven nights. Subjects were randomized to receive either KAPIDEX 30 mg or placebo orally every morning for four weeks. Study results showed that treatment with KAPIDEX 30 mg resulted in a greater percentage of nights without heartburn compared to placebo (73% vs. 36%, respectively, p<0.001). During the last seven days of treatment, KAPIDEX 30 mg also provided relief of nighttime heartburn and GERD-related sleep disturbances in a greater percentage of subjects (48% vs. 20%, and 70% vs. 48%, respectively, p<0.001 for both). Relief was defined as six of seven days without nighttime heartburn and no more than one night with mild heartburn, and six of seven days without GERD-related sleep disturbances.

About GERD

GERD, commonly known as acid reflux disease, affects nearly 19 million Americans. GERD is often characterized by frequent and persistent heartburn that occurs two or more days a week despite treatment and diet changes. GERD can affect both men and women, and symptoms are often triggered by certain foods, stress or pressure on the stomach. Up to 70 percent of GERD patients have non-erosive GERD, a term used to describe symptoms suggestive of GERD in patients with no endoscopic evidence of EE.

About KAPIDEX(TM) (dexlansoprazole) delayed release capsules

KAPIDEX (dexlansoprazole) delayed release capsules is a proton pump inhibitor (PPI), which decreases acid production by turning off many of the acid pumps in the stomach, thus helping to protect the esophagus from acidic reflux so that esophageal inflammation can heal. KAPIDEX combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. KAPIDEX, taken once daily, is approved for the healing of all grades of erosive esophagitis (EE) for up to eight weeks, maintaining healing of EE for up to six months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information

KAPIDEX is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with KAPIDEX use. Symptomatic response with KAPIDEX does not preclude the presence of gastric malignancy. The most commonly reported treatment-emergent adverse reactions (greater than or equal to 2%) include diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%). KAPIDEX must not be co-administered with atazanavir because atazanavir systemic concentrations may be substantially decreased. KAPIDEX may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding, which can lead to serious consequences. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please see the complete prescribing information and visit the KAPIDEX Web site at www.kapidex.com.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.

SOURCE Takeda Pharmaceuticals North America, Inc.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Confirms VASER Lipo Results Are Superior to Standard Liposuction
2. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
3. Delcath Systems, Inc. Completes Phase III Study Enrollment
4. AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed
5. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
6. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
7. comScore Study Finds the Internet a Key Component in Consumer Research on Prescriptions and Health Conditions
8. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
9. CVS Caremark Undertakes Multi-Year Study to Improve Patient Medication Adherence
10. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
11. DATATRAK Signs 6 Year Study with New Device Client
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... year-end 2015 results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 11, 2016 at 4:30 p.m. Eastern Time (1:30 p.m. ... http://www.neurocrine.com . --> Participants can access the ...
(Date:2/8/2016)... 8, 2016 --> ... report "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", ... over the forecast period of 2015 to 2020. The ... at CAGR of 10.5% from 2015 to 2020. ...
(Date:2/8/2016)... 8, 2016 Nueterra, the nation,s ... in the development of equity partnerships and ... has divided its interests between two new ... will continue the founding company,s private equity ... a national system of integrated provider networks ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest ... and 700 companies. Attendees also get to see the most incredible gardens and ... Home Show , at the Colorado Convention Center - 700 14th St. Denver CO, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
Breaking Medicine News(10 mins):